



## Supplementary file

**Table S1. Study characteristics.**

Primary Author	Year	Country	Blinding	ITT Sample	PP Sample	Treatment Arms	Outcomes Assessed	Timing of Outcome Assessment
Bagel J <sup>13</sup>	2017	United States	Double	102	97, 92*	Secukinumab 300 mg at baseline, weeks 1, 2, 3, then every 4 weeks from week 4 to 20 vs placebo	PSSI, IGA/PGA	Weeks 1 to 4, 8, 12, 16, 20, and 24
Buckley C <sup>23</sup>	2008	Canada, Finland, France, Ireland	Double	218	212	50 µg/G calcipotriol + 0.5 mg/G betamethasone dipropionate QD vs betamethasone dipropionate 0.5 mg QD	IGA/PGA, TSS, adverse events, treatment compliance, treatment duration, patient-reported treatment success	Baseline and weeks 1, 2, 4, 6, and 8
Elewski B <sup>14</sup>	2022	United States	Double	441	177	Brodalumab 210 mg for 12 weeks every 2 weeks vs placebo	PSSI	Baseline and weeks 1, 2, 4, 6, and 8
Bagel J <sup>15</sup>	2012	Canada, United States	Double	124	121	Etanercept 50 mg twice weekly during weeks 1 through 12 vs placebo	PSSI, ScPGA, PASI, pruritus, burning, erythema, scaling, thickness, relapse time, adverse events, Patient Global Assessment, % change in SSA involvement	Baseline and weeks 4, 8, 12, 16, 20, and 24
Bahraini P <sup>41</sup>	2018	Iran	Double	40	30	Tumeric Tonic twice daily for 9 weeks vs placebo	DLQI, PASI, erythema, scaling, thickness	Baseline and weeks 3, 6, and 9
Feldman SR <sup>9</sup>	2001	United States	Single	79	79	Betamethasone valerate BID vs betamethasone valerate QD	IGA/PGA, TSS, erythema, scaling, thickness	Baseline and week 4
Jemec GBE <sup>24</sup>	2008	Denmark, Canada, France, Norway, Spain, Portugal, Sweden	Double	1505	1310	50 ug calcipotriene + 0.5 mg betamethasone QD for up to 8 weeks vs calcipotriene/OI 50 ug QD for up to 8 weeks vs betamethasone dipropionate QD 0.5mg QD for up to 8 weeks vs placebo	IGA/PGA, TSS, erythema, scaling, thickness, adverse events, medication compliance	Baseline and weeks 1 to 8
Jury CS <sup>42</sup>	2000	UK	Double	28	24	Itraconazole 200mg QD for 14 days vs placebo	PASI, erythema, scaling, thickness, colonization of M. furfur	Baseline and weeks 2, 4, 6, and 8

Kragballe K <sup>25</sup>	2009	Belgium, Canada, Denmark, France, Sweden	Single	312	272	50 ug/g calcipotriene + 0.5 mg/g betamethasone QD for up to 8 weeks vs calcipotriene/OI 50 ug/g QD for up to 8 weeks	IGA/PGA, TSS, pruritus, erythema, scaling, thickness, relapse time, adverse time, Patient Global Assessment, treatment compliance	Baseline and weeks 1, 2, 4, 6, and 8
Liu L <sup>26</sup>	2020	China	Single	951	794	50 ug/g calcipotriene + 0.5 mg betamethasone QD for up to 28 weeks vs calcipotriene/OI 50 ug/g QD for up to 28 weeks	IGA/PGA, pruritus, erythema, scaling, thickness, adverse events, Patient Global Assessment	Baseline and weeks 4, 8, 12, 16, 20, 24, and 28
Ma L <sup>27</sup>	2016	China	Single	244	226	Calcipotriene + Betamethasone up to 100g vs Calcipotriene/OI up to 60ml BID	IGA/PGA, TSS, DLQI, pruritus, erythema, scaling, thickness, adverse events, Patient Global Assessment	Baseline and weeks 1, 2, and 4
Okubo Y <sup>40</sup>	2014	Japan	NR	37	31	0.05% betamethasone lotion and 2.5 ug/g maxacalcitol lotion 8 weeks vs 4 weeks	TSS, PASI, erythema, scaling, thickness, adverse events, extent of lesion and overall improvement in total sign score	Baseline and weeks 4, 8, and 16
van de Kerkhof PC <sup>28</sup>	2009	Netherlands, Denmark, UK, Ireland, Canada, Finland, Belgium, France, Germany	Double	1417	1265	50 ug/g calcipotriene + 0.5 mg/g betamethasone QD for up to 8 weeks vs betamethasone dipropionate QD 0.5 mg/g QD for up to 8 weeks vs calcipotriene/OI 50ug/g QD for up to 8 weeks	IGA/PGA, TSS, erythema, scaling, thickness, adverse events, Patient Global Assessment	Baseline and weeks 1, 2, 4, 6, and 8
Patel DS <sup>29</sup>	2020	United States	Double	302	281	Calcipotriene + betamethasone QD for 4 weeks vs betamethasone dipropionate QD for 4 weeks vs calcipotriene/OI QD for 4 weeks	IGA/PGA, TSS, PASI, erythema, scaling, thickness, adverse events	Baseline and weeks 1, two and 4
Rattanakaemakorn P <sup>21</sup>	2021	Thailand	Evaluator	30	27	Excimer Lamp + 10% LCD Cream vs Excimer Lamp	PSSI, Scalpdex, pruritus	Baseline, 20th visit, 30th visit, and four weeks from last treatment

Table S1 continues

Table S1. Study characteristics. (continued)

Primary Author	Year	Country	Blinding	ITT Sample	PP Sample	Treatment Arms	Outcomes Assessed	Timing of Outcome Assessment
Reich K <sup>16</sup>	2017	Germany, USA, Japan, Brazil	Double	3524	NR	Etanercept 50 mg twice weekly vs ixekizumab 160 mg and then 80 mg Q2W vs ixekizumab 160 mg and then 80 mg Q4W vs placebo	PSSI, IGA/PGA, DLQI, PASI, adverse events, body surface area	Baseline and every four weeks until week 60
Reygagne P <sup>30</sup>	2005	France, Germany, Belgium, Netherlands, Spain, Portugal, Italy, USA	Investigator	137	128	Clobetasol propionate shampoo QD vs calcipotriene/ol BID	IGA/PGA, TSS, pruritus, burning, erythema, thickness, adverse events, Patient Global Assessment	Baseline and weeks 2 and 4
Rich P <sup>43</sup>	2016	USA, Canada, France	Double	1255	824	Apremilast 30 mg BID vs placebo	ScPGA, PASI, NAPS	Baseline and weeks 2, 4, 8, 12, and 16
Saraceno R <sup>31</sup>	2014	Italy	NR	885	798	Calcipotriol/ene+ betamethasone dipropionate QD on demand vs 2x/weekly maintenance	IGA/PGA, TSS, adverse events, Patient Global Assessment, scalp surface area involvement, relapse	Baseline and weeks 2, 4, 8, and 12
Tyring S <sup>32</sup>	2010	United States	Double	177	158	Calcipotriol/ene+ betamethasone dipropionate QD up to 40g/week vs placebo	IGA/PGA, TSS, erythema, scaling, adverse events, Patient Global Assessment, serum calcium, albumin, BUN, creatinine at weeks 0, 2, 4	Baseline and weeks 2, 4, and 8
Van Voorhees S <sup>33</sup>	2020	USA, Canada	Double	303	252	Apremilast 30 mg BID for 16 weeks vs placebo	ScPGA, IGA/PGA, DLQI, PASI, adverse events, whole body itch NRS, scalp itch NRS	Baseline and weeks 2, 4, 8, 12, and 16
Zhou J <sup>22</sup>	2018	China	NR	80	68	UVA1 phototherapy vs narrow band UVB phototherapy	PSSI, DLQI, adverse events	Baseline and weeks 3, 6, and 10
Thaçi D <sup>20</sup>	2022	Germany	Unblinded	110	110	Risankizumab 150 mg at weeks 0, 4, 16 vs Fumaric Acid Esters 30mg QD at week 0 to a maximum dosage of 720 mg QD	PSSI, DLQI, adverse events	Every four weeks until week 24

Blauvelt A <sup>44</sup>	2017	USA, UK, Canada	Double	708	708	708	Guselkumab 100 mg at weeks 0, 4, 12, and Q8W through week 44 vs adalimumab 80 mg at week 0, 40 mg at week 1 and Q2W to week 47 vs placebo	DLQI, adverse events	Weeks 2, 4, and every four weeks until 48 weeks
Reich K <sup>34</sup>	2017	United States, Australia	Double	804	804	804	Guselkumab 100 mg at weeks 0, 4, 12, and 20 vs adalimumab 80 mg at week 0, 40 mg at week 1 and Q2W to week 23 vs placebo	IGA/PGA, adverse events	Weeks 2, 4, and every four weeks until 48 weeks
Ohtsuki M <sup>35</sup>	2018	Japan	Double	NR	NR	NR	Guselkumab 50 mg vs 100 mg at weeks 0, 4, and Q8W after vs placebo	IGA/PGA, adverse events	Baseline and every four weeks from week 16 to 52
Thaçi D <sup>36</sup>	2020	Germany	Unblinded	107	107	107	Guselkumab 100 mg at weeks 0, 4, and Q8W after vs fumaric acid esters	IGA/PGA, adverse events	Baseline and weeks 2, 4, and every four weeks until 24 weeks
Seo SJ <sup>17</sup>	2021	Korea	Double	NR	NR	NR	Brodalumab 210 mg at baseline, weeks 1, 2, 4, 6, 8, 10, and Q2W to 62 vs placebo	PSSI, adverse events	Every two weeks until week 64
Nakagawa H <sup>18</sup>	2016	Japan	Double	143	143	143	Brodalumab 70 mg vs 140 mg at baseline and weeks 1, 2, 4, 6, 8, 10 vs 210 mg vs placebo	PSSI, adverse events	Every two weeks until week 12
Reich K <sup>37</sup>	2021	Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russia, UK, and USA	Double	503	503	503	Bimekizumab 320 mg Q4W, ustekinumab 45 or 90 mg at week 0, 4 and Q12W vs placebo	IGA/PGA, adverse events	Baseline and week 1, 2, 4, and every four weeks until week 52
Gordon KB <sup>38</sup>	2021	Australia, Canada, Germany, Hungary, Poland, Russia, South Korea, UK, and USA	Double	NR	NR	384	Bimekizumab 320 mg Q4W vs placebo	IGA/PGA, adverse events	Baseline and every four weeks until week 56

Table S1 continues

Table S1. Study characteristics. (continued)

Primary Author	Year	Country	Blinding	ITT Sample	PP Sample	Treatment Arms	Outcomes Assessed	Timing of Outcome Assessment
Langle RG <sup>19</sup>	2015	Canada, USA	Double	105	105	Ixekizumab 10 mg vs 25 mg vs 75 mg vs 150 mg on weeks 0, 2, 4, 8, 12, 16 vs placebo	PSSI	Weeks 0, 1, 2, 4, 6, 8, 12, 16, and 20
Lebwohl MG <sup>39</sup>	2016	United States	Double	199	199	Calcipotriol/ene+ betamethasone dipropionate QD for 4 weeks vs calcipotriene/OI QD for 4 weeks vs betamethasone dipropionate QD for 4 weeks	IGA/PGA	Week 4
Bergstrom KB <sup>45</sup>	2003	United States	Single	32	29	Clobetasol propionate foam for 14 days vs clobetasol propionate solution for 14 days	DLQI, PASI	14 Days
Stein Gold L <sup>46</sup>	2022	USA, Canada	Double	411	411	Apremilast 30 mg BID vs placebo	ScPGA	Weeks 2, 4, 8, 12, and 16

*Abbreviations:* BID: Two times a day; QD: Once a day; DLQI: Dermatology Life Quality Index; IGA: Investigator Global Assessment; PGA: Physician Global Assessment; NAPS: Nail Psoriasis Severity Index; NRS: Numeric Rating Scale; PASI: Psoriasis Area and Severity Index; PSSI: Psoriasis Scalp Severity Index; SSA: Scalp Surface Area; TSS: Total Sign Score; ScPGA: static Physician Global Assessment.

Notes\* 97 patients completed treatment period 1 (12 weeks) and 92 patients completed treatment period two (24 weeks)